Center-Authored Papers

Filters: Author is Decamp, Allan C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH et al..  2014.  Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.. Journal of virology. Abstract
Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E et al..  2013.  Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.. PloS one. 8(1):e53629. Abstract
C
Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, Decamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M et al..  2015.  Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.. PLoS computational biology. 11(2):e1003973. Abstract
G
Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A et al..  2011.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.. Nature medicine. 17(3):366-71. Abstract
H
Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, Sesterhenn F, Ereño-Orbea J, Kalyuzhniy O, Deresa I et al..  2016.  HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.. Science (New York, N.Y.). 351(6280):1458-63. Abstract
Frahm N, Decamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP et al..  2012.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67. Abstract
I
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, Decamp AC, Carrico C, Menis S, Magaret CA et al..  2012.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.. Nature. 490(7420):417-20. Abstract
Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT et al..  2008.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.. Journal of virology. 82(24):12449-63. Abstract
L
Safrit JT, Tomaras GD, Hanke T, Decamp AC, Voronin Y.  2016.  The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field.. AIDS research and human retroviruses. Abstract
P
Aiyegbo MS, Shmelkov E, Dominguez L, Goger M, Battacharya S, Decamp AC, Gilbert PB, Berman PW, Cardozo T.  2017.  Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure.. PloS one. 12(1):e0170530. Abstract
R
Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H et al..  2011.  Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections.. PLoS pathogens. 7(9):e1002209. Abstract
S
Huang Y, DiazGranados C, Janes H, Huang Y, Decamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M et al..  2016.  Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65. Abstract
Fiore-Gartland A, Kullman N, Decamp AC, Clenaghan G, Yang W, Magaret CA, Edlefsen PT, Gilbert PB.  2017.  SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials.. Bioinformatics (Oxford, England). 33(15):2386-2388. Abstract
V
Perez LG, Martinez DR, Decamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H et al..  2017.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.. PloS one. 12(7):e0180720. Abstract